ArticleBMC complementary and alternative medicine2019
Anti-viral activity of culinary and medicinal mushroom extracts against dengue virus serotype 2: an in-vitro study.
Article in BMC complementary and alternative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 50 citations in OpenAlex.
- Mushroom marvels: understanding their role in human health.Frontiers in nutrition · 2025Review
- Protective effects of tiger milk mushroom extract (xLr®) against UVB irradiation inJournal of traditional and complementary medicine · 2025Article
- Wild Mushrooms as a Source of Bioactive Compounds and Their Antioxidant Properties-Preliminary Studies.Foods (Basel, Switzerland) · 2024Article
- Correction: Anti-viral activity of culinary and medicinal mushroom extracts against dengue virus serotype 2: an in-vitro study.BMC complementary medicine and therapies · 2023Article
- The Wound Healing Potential ofMycobiology · 2023Review
- A concise review of mushrooms antiviral and immunomodulatory properties that may combat against COVID-19.Food chemistry advances · 2022Review
- In vitro assessment of multipotential therapeutic importance of Hericium erinaceus mushroom extracts using different solvents.Bioresources and bioprocessing · 2022Article
- Medicinal Fungi with Antiviral Effect.Molecules (Basel, Switzerland) · 2022Review
- Hit-to-Lead Short Peptides against Dengue Type 2 Envelope Protein: Computational and Experimental Investigations.Molecules (Basel, Switzerland) · 2022Article
- Identification of potential edible mushroom as SARS-CoV-2 main protease inhibitor using rational drug designing approach.Scientific reports · 2022Article
- Can medicinal mushrooms have prophylactic or therapeutic effect against COVID-19 and its pneumonic superinfection and complicating inflammation?Scandinavian journal of immunology · 2021Review
- Natural Compounds With Antimicrobial and Antiviral Effect and Nanocarriers Used for Their Transportation.Frontiers in pharmacology · 2021Review
- Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19.Phytotherapy research : PTR · 2020Review
- Antiviral Natural Products for Arbovirus Infections.Molecules (Basel, Switzerland) · 2020Review
- Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.Integrative medicine (Encinitas, Calif.) · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue is a mosquito-borne viral infection that has become a major public health concern worldwide. Presently, there is no specific vaccine or treatment available for dengue viral infection.
methodsLignosus rhinocerotis, Pleurotus giganteus, Hericium erinaceus, Schizophyllum commune and Ganoderma lucidium were selected for evaluation of their in-vitro anti-dengue virus serotype 2 (DENV-2) activities. Hot aqueous extracts (HAEs), ethanol extracts (EEs), hexane soluble extracts (HSEs), ethyl acetate soluble extracts (ESEs) and aqueous soluble extracts (ASEs) were prepared from the selected mushrooms. The cytotoxic effects of the extracts were evaluated by the MTT assay. The anti-DENV-2 activities of the extracts were evaluated in three different assays: simultaneous, attachment and penetration assays were perfomed using plaque reduction assays and RT-qPCR assays. The effect of the addition time on viral replication was assessed by the time of addition assay, and a virucidal assay was carried out to evaluate the direct effect of each mushroom extract on DENV-2. The chemical composition of glucans, and the protein and phenolic acid contents in the extracts were estimated.
resultsWe found that the HAEs and ASEs of L. rhinocerotis, P. giganteus, H. erinaceus and S. commune were the least toxic to Vero cells and showed very prominent anti-DENV2 activity. The 50% inhibitory concentration (IC
conclusionThese findings demonstrated the potential of mushroom extracts as anti-dengue therapeutic agents with less toxic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.